CSLHAM:CSJ +0.07%73 Interest Coverage is 10.07 as of Dec. 2025, which is 30% below its 10-year median of 14.29. GuruFocus rates HAM:CSJ with a GF Score™ of 73/100 and a GF Value™ of €170.71 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 377 Biotechnology companies, CSL ranks worse than 76.92% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. CSL's
Operating Income
for the
six
months ended in Dec. 2025 was €1,626 Mil. CSL's Interest Expense for the
six
months ended in Dec. 2025 was €-161 Mil.
CSL's interest coverage for the quarter that ended in Dec. 2025 was 10.07.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for CSL's Interest Coverage or its related term are showing as below:
HAM:CSJ'
s Interest Coverage Range Over the Past 10 Years
Min: 5.15 Med: 14.29 Max: 16.22
Current: 10.07
HAM:CSJ's Interest Coverage is ranked worse than 76.92% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs HAM:CSJ: 10.07
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
CSL Interest Coverage Related Terms
CSL Interest Coverage Historical Data
* Premium members only.
The historical data trend for CSL's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HAM:CSJ vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, CSL's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Interest Coverage distribution charts can be found below:
* The bar in red indicates where CSL's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (HAM:CSJ) has a Interest Coverage of 10.07 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on CSL and its competitors. This is 30% below median its historical median of 14.29. Over the past decade, CSL's Interest Coverage has ranged from 5.15 to 16.22. According to the industry distribution chart, CSL ranks #290 out of 377 companies in the Biotechnology industry, placing it in the top 76.9%.
Is CSL's Interest Coverage too high?
CSL's current Interest Coverage of 10.07 is 30% below median its 10-year median of 14.29. Over the past 10 years, this metric has ranged from a low of 5.15 to a high of 16.22. The Biotechnology industry median Interest Coverage is 106.07. CSL's value of 10.07 is 90.5% below this industry median. Based on the distribution chart, CSL ranks #290 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #290 out of 377 companies for Interest Coverage. This places CSL in the lower half of its industry. The industry median Interest Coverage is 106.07. CSL's value of 10.07 is 90.5% below this benchmark. Historically, CSL's own Interest Coverage has ranged from 5.15 to 16.22 over the past decade. While the company's 10-year median is 14.29 vs. the industry median of 106.07, CSL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Interest Coverage of 10.07 is 90.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on CSL and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Interest Coverage is 10.07, which is 30% below median its own 10-year median of 14.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €170.71, compared to a current price of €68.23 — trading 60% below its estimated fair value. The current Interest Coverage is 10.07, which is 30% below median its 10-year median of 14.29 and 90.5% below the Biotechnology industry median of 106.07. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For CSL (HAM:CSJ), the current Interest Coverage is 10.07 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (HAM:CSJ) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of €68.23 is trading 60% below its estimated GF Value™ of €170.71.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for HAM:CSJ:
Interest Coverage: 10.07 (30% below median its 10-year median of 14.29)
GF Value™: €170.71 vs. price of €68.23 (60% below fair value)
Industry Position: 90.5% below the Biotechnology median (#290 of 377)
No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for HAM:CSJ
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:CSJ has been successfully added to your 
